Published in Mol Cell Biol on December 01, 2005
Runx1 exon 6-related alternative splicing isoforms differentially regulate hematopoiesis in mice. Blood (2014) 1.43
AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol Cell Biol (2006) 1.18
The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood (2007) 1.17
Cell cycle and developmental control of hematopoiesis by Runx1. J Cell Physiol (2009) 1.16
Requirement for cyclin D3 in germinal center formation and function. Cell Res (2010) 1.16
The Arabidopsis D-type cyclin CYCD4 controls cell division in the stomatal lineage of the hypocotyl epidermis. Plant Cell (2007) 1.15
Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci U S A (2008) 1.14
t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. Blood (2008) 1.07
The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes. J Cell Sci (2008) 1.06
Essential role for cyclin D3 in granulocyte colony-stimulating factor-driven expansion of neutrophil granulocytes. Mol Cell Biol (2006) 1.04
The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes. J Cell Physiol (2010) 1.01
Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. Blood (2007) 0.99
Is Runx a linchpin for developmental signaling in metazoans? J Cell Biochem (2009) 0.90
Post-translational modifications of Runx1 regulate its activity in the cell. Blood Cells Mol Dis (2009) 0.90
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol (2016) 0.90
Quantitative trait loci for porcine baseline erythroid traits at three growth ages in a White Duroc x Erhualian F(2) resource population. Mamm Genome (2008) 0.89
Transcription factors Runx1 to 3 are expressed in the lacrimal gland epithelium and are involved in regulation of gland morphogenesis and regeneration. Invest Ophthalmol Vis Sci (2013) 0.88
CBFB-MYH11 hinders early T-cell development and induces massive cell death in the thymus. Blood (2006) 0.87
Runx expression is mitogenic and mutually linked to Wnt activity in blastula-stage sea urchin embryos. PLoS One (2008) 0.85
Cyclin D3 critically regulates the balance between self-renewal and differentiation in skeletal muscle stem cells. Stem Cells (2013) 0.80
Blood and immune cell engineering: Cytoskeletal contractility and nuclear rheology impact cell lineage and localization: Biophysical regulation of hematopoietic differentiation and trafficking. Bioessays (2015) 0.75
RNA-Seq analysis of Gtf2ird1 knockout epidermal tissue provides potential insights into molecular mechanisms underpinning Williams-Beuren syndrome. BMC Genomics (2016) 0.75
Cyclin D3 deficiency inhibits skin tumor development, but does not affect normal keratinocyte proliferation. Oncol Lett (2017) 0.75
Cancer cell cycles. Science (1996) 21.29
pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res (1990) 12.75
AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell (1996) 9.74
Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell (1994) 9.25
D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol (1994) 7.35
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell (1993) 7.19
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet (1999) 6.61
Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A (1996) 6.29
The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J (1996) 4.55
AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med (2004) 4.00
Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell (2003) 3.86
Transcription factors, normal myeloid development, and leukemia. Blood (1997) 3.71
Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer (2002) 3.18
Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci U S A (1998) 3.07
Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J (1994) 2.91
Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol (1997) 2.40
Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid, and erythroid development. Genes Dev (1994) 2.39
RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood (2003) 2.21
Groucho/TLE/R-esp proteins associate with the nuclear matrix and repress RUNX (CBF(alpha)/AML/PEBP2(alpha)) dependent activation of tissue-specific gene transcription. J Cell Sci (2000) 2.08
Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. Proc Natl Acad Sci U S A (1993) 2.07
Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res (1992) 1.95
Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood (2000) 1.91
Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol Cell Biol (1998) 1.82
Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol (1994) 1.77
Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol Cell Biol (1998) 1.69
D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res (1999) 1.67
Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase. Mol Cell Biol (1997) 1.63
Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res (2001) 1.58
An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J (1995) 1.56
Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol Cell Biol (1996) 1.55
Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene (2000) 1.52
Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol (1999) 1.48
Role of RUNX1 in adult hematopoiesis: analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage expression. Blood (2003) 1.46
AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene (2001) 1.42
Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J Biol Chem (2000) 1.37
Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood (2001) 1.36
AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression. J Biol Chem (2004) 1.31
Sustained activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells. J Biol Chem (1997) 1.30
The Runx1 transcription factor inhibits the differentiation of naive CD4+ T cells into the Th2 lineage by repressing GATA3 expression. J Exp Med (2003) 1.28
D-type cyclins repress transcriptional activation by the v-Myb but not the c-Myb DNA-binding domain. EMBO J (1998) 1.26
Cyclin D1 Is a Ligand-independent Co-repressor for Thyroid Hormone Receptors. J Biol Chem (2002) 1.23
Cyclin D3 is essential for megakaryocytopoiesis. Blood (1995) 1.15
RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53. Oncogene (2004) 1.12
SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo. Oncogene (2003) 1.10
Interaction of p58(PITSLRE), a G2/M-specific protein kinase, with cyclin D3. J Biol Chem (2002) 1.06
Cyclin D1 as a cellular proto-oncogene. Semin Cancer Biol (1995) 1.05
Transcriptional regulation of the human MIP-1alpha promoter by RUNX1 and MOZ. Nucleic Acids Res (2003) 1.03
AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J Biol Chem (2004) 1.00
AML1 stimulates G1 to S progression via its transactivation domain. Oncogene (2002) 0.95
Transcription factor fusions in acute leukemia: variations on a theme. Oncogene (2002) 0.93
AML1 (CBFalpha2) cooperates with B cell-specific activating protein (BSAP/PAX5) in activation of the B cell-specific BLK gene promoter. J Biol Chem (1999) 0.88
Cyclin D3 and megakaryocyte development: exploration of a transgenic phenotype. Stem Cells (1998) 0.87
The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1. Blood (1998) 0.86
Requirement of transcription factor AML1 in proliferation of developing thymocytes. Immunol Lett (2003) 0.85
Molecular biology of leukemia and lymphoma. Rev Invest Clin (1994) 0.77
Analysis of the modulation of transcriptional activity in myelopoiesis and leukemogenesis. Methods (1999) 0.77
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 7.48
Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology (2006) 4.61
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med (2007) 4.50
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet (2004) 4.45
Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol (2007) 4.27
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell (2011) 4.04
Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat Immunol (2006) 3.98
Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood (2002) 3.97
Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity (2004) 3.84
C/EBPbeta is required for 'emergency' granulopoiesis. Nat Immunol (2006) 3.53
UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem (2002) 3.52
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell (2008) 2.87
UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J (2006) 2.84
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood (2007) 2.77
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res (2005) 2.72
Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol Cell Biol (2004) 2.70
Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med (2013) 2.70
TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood (2008) 2.64
Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood (2005) 2.64
The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages. Genes Dev (2006) 2.62
Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med (2004) 2.59
Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci U S A (2005) 2.59
Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol (2011) 2.51
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med (2006) 2.36
The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation. EMBO J (2007) 2.34
Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood (2009) 2.26
Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev (2003) 2.24
High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem (2003) 2.24
The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem (2005) 2.19
The 8;21 translocation in leukemogenesis. Oncogene (2004) 2.18
Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem Biophys Res Commun (2005) 2.18
Cytokine signals modulated via lipid rafts mimic niche signals and induce hibernation in hematopoietic stem cells. EMBO J (2006) 2.18
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet (2007) 2.18
BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood (2010) 2.17
Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res (2010) 2.14
Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev (2008) 2.12
In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood (2012) 2.12
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood (2004) 2.11
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet (2006) 2.10
DNMT1-interacting RNAs block gene-specific DNA methylation. Nature (2013) 2.04
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res (2008) 2.00
RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells. Blood (2013) 2.00
Essential and instructive roles of GATA factors in eosinophil development. J Exp Med (2002) 1.98
ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J Biol Chem (2008) 1.98
Interaction of FANCD2 and NBS1 in the DNA damage response. Nat Cell Biol (2002) 1.96
Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol (2005) 1.96
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res (2008) 1.95
Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice. J Exp Med (2006) 1.94
PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. Genes Dev (2008) 1.90
Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia. Cancer Cell (2013) 1.89
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med (2006) 1.88
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer (2007) 1.87
ISG15: the immunological kin of ubiquitin. Semin Cell Dev Biol (2004) 1.87
Role of SOX17 in hematopoietic development from human embryonic stem cells. Blood (2012) 1.86
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J (2003) 1.85
Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet (2005) 1.82
A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut (2013) 1.80
Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol (2006) 1.80
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res (2006) 1.78
Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell (2009) 1.78
Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J (2005) 1.77
Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica (2008) 1.74
Mice lacking the ISG15 E1 enzyme UbE1L demonstrate increased susceptibility to both mouse-adapted and non-mouse-adapted influenza B virus infection. J Virol (2008) 1.73
Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med (2005) 1.72
Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells. Blood (2011) 1.66
A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest (2007) 1.63
Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol Cell Biol (2004) 1.61
Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol (2008) 1.61
Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol (2009) 1.61
Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood (2009) 1.61
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci U S A (2004) 1.60
ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood (2005) 1.59
The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood (2002) 1.58
ISG15: a ubiquitin-like enigma. Front Biosci (2005) 1.58
C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J (2003) 1.58
ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. Genes Dev (2007) 1.57
Regulation of Rap2A by the ubiquitin ligase Nedd4-1 controls neurite development. Neuron (2010) 1.57
Dysregulation of protein modification by ISG15 results in brain cell injury. Genes Dev (2002) 1.57
MOZ is essential for maintenance of hematopoietic stem cells. Genes Dev (2006) 1.56
The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res (2008) 1.56
Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood (2012) 1.56
Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool. Blood (2011) 1.54
Down-regulation and antiproliferative role of C/EBPalpha in lung cancer. Cancer Res (2002) 1.53
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol (2008) 1.53
Granulocyte inducer C/EBPalpha inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions. Blood (2002) 1.53
SON controls cell-cycle progression by coordinated regulation of RNA splicing. Mol Cell (2011) 1.52
C/EBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment. Blood (2007) 1.52
The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cells. Blood (2003) 1.51
Poised lineage specification in multipotential hematopoietic stem and progenitor cells by the polycomb protein Bmi1. Cell Stem Cell (2010) 1.48
Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential. Blood (2013) 1.46
Endomucin, a CD34-like sialomucin, marks hematopoietic stem cells throughout development. J Exp Med (2005) 1.44